newsfilter
← Latest News
PR Newswire·

Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

First patient in fifth cohort exhibiting stable disease 90 days after treatmentMultiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to datePatients in